

Three-Dimensional Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibitors[§]

Quanwen Li, Albert B. Chow, and Raymond R. Mattingly

Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan

Received August 12, 2009; accepted November 30, 2009

ABSTRACT

Tumor cells that are grown in three-dimensional (3D) cell culture exhibit relative resistance to cytotoxic drugs compared with their response in conventional two-dimensional (2D) culture. We studied the effects of targeted agents and doxorubicin on 2D and 3D cultures of human breast cell lines that represent the progression from normal epithelia (modeled by MCF10A cells) through hyperplastic variants to a dysplastic/carcinoma phenotype (MCF10.DCIS cells), variants transformed by expression of activated Ras, and also a basal-subtype breast carcinoma cell line (MDA-MB-231). The results showed the expected relative resistance to the cytotoxic agent doxorubicin in 3D cultures, with greater resistance in normal and hyperplastic cells than in carcinoma models. However, the response to the targeted inhibitors was more complex. Inhibition of mitogen-activated protein kinase kinase (MEK) by either 1,4-diamino-2,3-

dicyano-1,4-bis(methylthio)butadiene (U0126) or 2-(2-chloro-4-iodo-phenylamino)-*N*-cyclopropylmethoxy-3,4-difluoro-benzamide (CI-1040, PD184352) produced a similar inhibition of the growth of all the MCF10 cell lines in 2D. In 3D culture, the normal and hyperplastic models exhibited some resistance, whereas the carcinoma models became far more sensitive to MEK inhibition. Increased sensitivity to MEK inhibition was also seen in MDA-MB-231 cells grown in 3D compared with 2D. In contrast, inhibition of phosphatidylinositol 3'-kinase activity by wortmannin had no significant effect on the growth of any of the cells in either 2D or 3D. Our conclusion is that 3D culture models may not only model the relative resistance of tumor cells to cytotoxic therapy but also that the 3D approach may better identify the driving oncogenic pathways and critical targeted inhibitors that may be effective treatment approaches.

Although oncogenic mutation of Ras is a relatively uncommon event in human breast cancers, there is prevalent functional activation of Ras signaling caused by alterations such as overexpressed growth factor receptors (von Lintig et al., 2000; Eckert et al., 2004). Of the several pathways downstream of activated Ras, extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) signal-

ing has been strongly implicated as a driver of the malignant phenotype and potential therapeutic target for breast and other cancers (McCubrey et al., 2007; Roberts and Der, 2007; McGlynn et al., 2009). Activation of this pathway may be particularly important, for example, in the basal or triple-negative subtype of breast cancer that is notably resistant to current therapies (Mirzoeva et al., 2009). Major preclinical and clinical effort has been focused on the MAPK kinases (MEKs) that are immediately upstream and critical for activation of ERK MAPKs (Allen et al., 2003; Rinehart et al., 2004).

Most in vitro preclinical therapeutic development for carcinomas has relied on traditional cell culture systems that grow cell lines attached to dishes [two-dimensional (2D) cell culture]. However, it has long been realized that cells grown in three-dimensional (3D) matrices can show relative resistance to chemotherapeutic drugs (Weaver et al., 2002). This

This work was supported in part by the National Institutes of Health National Cancer Institute [Grant R01-CA131990]; and the Susan G. Komen Breast Cancer Foundation. This project was aided by the Cellular Imaging Core Facility, which was supported by the National Institutes of Health National Institute of Environmental Health Sciences [Grant P30-ES06639] and the National Institutes of Health National Cancer Institute [Grant P30-CA22453].

Article, publication date, and citation information can be found at <http://jpet.aspetjournals.org>.

doi:10.1124/jpet.109.160390.

[§]The online version of this article (available at <http://jpet.aspetjournals.org>) contains supplemental material.

ABBREVIATIONS: ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; 2D, two-dimensional; 3D, three-dimensional; rBM, reconstituted basement membrane; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline; FBS, fetal bovine serum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; CI-1040/PD184352, 2-(2-chloro-4-iodo-phenylamino)-*N*-cyclopropylmethoxy-3,4-difluoro-benzamide; U0126, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene; U0124, 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene; DMSO, dimethyl sulfoxide; GI₅₀, concentration of drug required to inhibit growth by 50%; PD98059, 2'-amino-3'-methoxyflavone.

property has been termed multicellular resistance and proposed to be more representative of tumor response *in vivo* than that found in 2D cell culture (Croix et al., 1996; Green et al., 1999; Desoize and Jardillier, 2000).

Culture of breast epithelial cells in 3D in reconstituted basement membrane (rBM) has been developed and refined by several groups, notably those of Bissell and Brugge (Debnath et al., 2003; Schmeichel and Bissell, 2003). We have recently adapted the rBM overlay 3D culture protocol to the MCF10 premalignant progression series of cells to provide an *in vitro* model of the stages of normal breast epithelia through hyperplasia, atypical hyperplasia, to ductal carcinoma *in situ* (Li et al., 2008). In this study, we systematically compare the effects of MEK inhibition on 2D and 3D cultures of the MCF10 progression series, plus MCF10 variants that are transformed by high level expression of activated H-Ras and N-Ras oncogenes, and the basal breast cancer cell line MDA-MB-231. Whereas MEK inhibition has a similar inhibitory effect on all the MCF10 variant cell lines when grown in 2D culture, 3D rBM culture reveals a striking selectivity for inhibition of the carcinoma models that is in marked contrast to a relative resistance in the normal and hyperplastic models. The results from this study suggest that 3D rBM overlay culture may be an improved system for preclinical screening of Ras pathway inhibitors.

Materials and Methods

Reagents. Dulbecco's modified Eagle's medium (DMEM)/F12, horse serum, phosphate-buffered saline (PBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), human epithelial growth factor, and insulin were purchased from Invitrogen (Carlsbad, CA). DMEM, trypsin/EDTA solution, and penicillin-streptomycin were obtained from Cellgro (Herndon, VA). Fetal bovine serum (FBS) was from HyClone Laboratories (Logan, UT). Basement membrane matrix (Matrigel) was obtained from BD Biosciences (San Jose, CA). Protease inhibitor mixture tablets were obtained from Roche Diagnostics (Indianapolis, IN). The MEK inhibitor PD184352 (or CI-1040) was supplied by Pfizer (New York, NY). The MEK inhibitor U0126 and its inactive analog U0124 were purchased from Calbiochem (San Diego, CA). Enhanced chemiluminescence Western blotting detection reagents were purchased from GE Healthcare (Little Chalfont, Buckinghamshire, UK). Doxorubicin, hydrocortisone, the phosphatidylinositol 3'-kinase inhibitor wortmannin, and other chemicals were from Sigma-Aldrich (St. Louis, MO). Rabbit anti-phospho-Akt (Ser473) and anti-total ERK1/2 antibodies were purchased from Cell Signaling Technology (Danvers, MA). Mouse anti-phospho-Erk1/2 antibody was from Sigma-Aldrich. Mouse anti-tubulin antibody was obtained from Developmental Studies Hybridoma Bank (Iowa City, IA). Horseradish peroxidase-conjugated donkey anti-mouse IgG and horseradish peroxidase-conjugated donkey anti-rabbit antibodies were purchased from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA).

Cell Lines and Maintenance. MCF10A human breast epithelial progression series of cells (MCF10A, NeoT, AT1, and DCIS) were obtained from the Cell Lines Resource (Karmanos Cancer Institute, Detroit, MI). Retroviral transformed MCF10A cell lines stably expressing constitutively active H-RasD12 (H-Ras) or active N-RasD12 (N-Ras) were gifts from Dr. Hyeon-Reh Choi Kim (Department of Pathology, Wayne State University). Human breast cancer cell line MDA-MB-231 was a gift from Dr. Bonnie F. Sloane (Wayne State University). MCF10A series of cells were maintained as monolayers at 37°C, 5% CO₂ in growth medium: DMEM/F12 containing 5% horse serum, 20 ng/ml epidermal growth factor, 10 µg/ml insulin, 0.5 µg/ml hydrocortisone, 50 U/ml penicillin, and 50 µg/ml streptomycin.

MDA-MB-231 cells were maintained as monolayers in DMEM containing 10% FBS, 50 U/ml penicillin, and 50 µg/ml streptomycin.

2D Culture Model and MTT Assay. Live cells can convert MTT into an insoluble dye formazan that can be solubilized by dimethyl sulfoxide (DMSO) and measured using a spectrometer as an indicator of live cell numbers. These studies were performed largely as we described previously (Li et al., 2008). In brief, 10³ trypsinized cells were seeded per well containing 200 µl of growth medium with inhibitors or vehicle in 96-well plates and cultured for 3 days. Then 20 µl of MTT stock solution (5 mg/ml in PBS) was added per well, and the plates were incubated for 4 h. The medium was removed, and the formazan precipitate was dissolved in 150 µl of DMSO per well. The absorbance values were measured using a plate reader (SpectraFluor Plus; Tecan, Salzburg, Austria) at the wavelength of 485 nm.

3D Cell Culture Model. The 3D rBM culture model of the MCF10 variants was used as described previously (Li et al., 2008) except that the media were changed every 3 days rather than every 4 days. The 3D rBM culture of the MDA-MB-231 cells was similar except that the medium used was DMEM containing 2.5% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, and supplemented with 2% (v/v) of Matrigel. After culture for 9 days, the cells were fixed with 4% paraformaldehyde for 20 min, quenched with 0.75% glycine in PBS three times, 10 min each time, and subjected to microscopic imaging.

Imaging and Quantification of Spheroidal Structures. Growth of cells in 3D rBM overlay culture can be assayed by measurement of the diameter of structures formed (Wang et al., 2002). Fixed cells were imaged with an LSM 510 confocal microscope (Carl Zeiss GmbH, Jena, Germany) using a 5× objective dipping lens. Tile-scan mode was used to obtain a 5 × 5 phase contrast tile image that covered the whole area of the Matrigel on a coverslip. The images were converted into tagged image file (.tif) files with the actual image size information using the software provided by Zeiss. The diameters of the spheroidal structures were measured using Adobe Photoshop version CS2 software (Adobe Systems, Mountain View, CA). In brief, the latitudinal diameters from 100 spheroidal structures of each sample were measured in a blinded protocol relative to the experimental design.

Statistical Analysis. Data from the cell proliferation assays were plotted on logarithmic assays of drug concentration using Prism software (GraphPad Software Inc., San Diego, CA) to calculate the concentration of drug required for 50% inhibition of cell growth (GI₅₀) by nonlinear regression curve fitting with sigmoidal dose-response (variable-slope) parameter. To compare GI₅₀ values for statistically significant differences, the *F* test was used with a threshold of *p* < 0.05.

Western Blot Assays. Lysates from 2D cultures were prepared as described previously (Li and Mattingly, 2008). To obtain sufficient material for Western blotting from 3D rBM cultures, the overlay culture process was adapted to be performed on 35-mm culture dishes rather than 12-mm diameter coverslips. After treatment, the cultures were briefly washed with PBS and solubilized in a buffer designed for both lysis and loading of SDS-polyacrylamide gel electrophoresis: 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 10 mM sodium pyrophosphate, 2 mM EDTA, 1% (v/v) Nonidet P40, 1% (v/v) 2-mercaptoethanol, 10% (v/v) glycerol, 2% (w/v) SDS, 50 mM sodium fluoride, 0.2 mM sodium orthovanadate, 0.005% (w/v) bromophenol blue, and supplemented with protease inhibitor mixtures according to the manufacturer's instructions. The cell lysates were subjected to brief sonication and heated in 100°C for 5 min and loaded onto SDS-polyacrylamide gels for electrophoresis. The proteins from the gel were transferred onto nitrocellulose membrane, blocked with 2% milk solution, and probed for specific target proteins with corresponding antibodies. Because protein concentrations could not be used to standardize the lysates (because of the presence of the rBM), the lysates were initially loaded based on volume and tested for content of tubulin by Western blotting. If necessary, loading adjustments were made to equalize the tubulin contents of the samples.

Results

The inhibitors of MEK are among the most selective of known kinase inhibitors, and the availability of structurally distinct agents, such as CI-1040 and U0126, provides a further approach to confirm that effects are caused by target block (Bain et al., 2007). We recently investigated the effects of inhibition of ERK MAPK activation in 2D cultures of Ras-transformed breast epithelial cells and found that it induced the relocalization of E-cadherin to cell-cell junctions (Li and Mattingly, 2008). In that study, 1 μ M CI-1040 or 10 μ M U0126 was sufficient to strongly inhibit ERK activation and induce reversion of transformed phenotypes but did not lead to a complete block in cell proliferation. Because inhibition of a driving oncogenic pathway might be expected to have a more profound effect on proliferation (Sharma and Settleman, 2007), we investigated whether this result suggested that either proliferation was driven by other pathways or else that the 2D cell culture model was not the most appropriate one for these assays.

We established 3D rBM overlay cultures of MCF10A breast epithelial cells and variants that are driven by expression of activated Ras and tested for growth inhibition by inhibition of MEK, inhibition of phosphatidylinositol 3'-kinase, and by the cytotoxic agent doxorubicin (Fig. 1). The data show that the MCF10A model of normal breast epithelial cells formed the expected acinar morphology and exhibited significant resistance to all the targeted agents tested. The cells transformed by high-level expression of either H-Ras or N-Ras exhibited

prominent but distinct hyperproliferative phenotypes in the 3D matrix. The MCF10.H-Ras cells produced extensive stellate structures, whereas the MCF10.N-Ras cells produced large and poorly organized clumps of cells. In further contrast to the MCF10A cells, the H-Ras and N-Ras cells were completely inhibited in their proliferation by either of the two MEK inhibitors. As a further control, we used the inactive structural analog U1024 (Favata et al., 1998) and found that it had no effect on proliferation. The MCF10.DCIS line, which we have previously shown to have a lower level of expression of activated H-Ras than is found in the MCF10.H-Ras cells (Li and Mattingly, 2008) and a moderately dysplastic character in 3D rBM overlay culture (Li et al., 2008), showed an intermediate phenotype, with strong but incomplete inhibition of proliferation after MEK inhibition.

To check that the MEK inhibitors were fully inhibiting the target in all the 3D rBM overlay cultures, we assayed for the levels of dually phosphorylated ERK1/2 MAPKs. In addition to the cell lines shown in Fig. 1, we also tested the effect on the MCF10.NeoT and MCF10.AT1 variants that are intermediate in the progression series between MCF10A and MCF10.DCIS cells, and that model hyperplasia and atypical hyperplasia, respectively (Li and Mattingly, 2008). The results show that ERK1/2 MAPKs are strongly activated in 3D rBM overlay cultures of MCF10.DCIS, MCF10.H-Ras, and MCF10.N-Ras cells and that this activation can be completely blocked by either U0126 or CI-1040 (Fig. 2). Levels of ERK1/2 MAPK activation in the MCF10A, MCF10.NeoT, and




Fig. 1. Effects of small molecule inhibitors on the growth of MCF10 cell variants in 3D rBM overlay cultures. Cells were incubated for 9 days in 3D rBM overlay cultures under control (DMSO vehicle) or drug treatment conditions. Inhibitors used were U0126 at 10 μ M, U0124 at 10 μ M, wortmannin at 200 nM, CI-1040 at 100 nM, and doxorubicin at 1 μ M. Phase-contrast images are shown. Scale bar, 100 μ m.




Fig. 2. Inhibition of ERK activation by MEK inhibitors in 3D rBM overlay cultures of MCF10 cell variants. Cells were incubated for 1 day in 3D rBM overlay cultures, and then either DMSO vehicle or inhibitor (10 μ M U0126 or 1 μ M CI-1040) was added for 24 h as shown. Lysates were prepared and subjected to Western blotting for active, dually phosphorylated ERK1/2 and for tubulin to confirm equal loading. The blots were also stripped and reprobed for total ERK1/2 as described previously (Mattingly et al., 2001). Results are representative of three independent experiments.

MCF10.AT1 cells were extremely low in 3D rBM overlay culture [particularly compared with our previous results on the robust activation present in 2D culture (Li and Mattingly, 2008)], but that basal level could also be blocked by MEK inhibition.

To investigate the relative sensitivity and resistance of the MCF10A breast epithelial cells and variants to MEK inhibition in 2D and 3D culture, we defined the dose-response of growth inhibition (Fig. 3). Proliferation was assayed in 2D culture by MTT assay (Li et al., 2008), whereas growth in 3D rBM overlay cultures was defined by measurement of the size of structures formed (Wang et al., 2002). The results showed that all the cell lines had a similar sensitivity to growth inhibition by U0126 or CI-1040 when the cells were cultured in 2D (Fig. 3, A and C). The concentration of drug required to

inhibit growth by 50% (GI_{50}) was 1.8 to 4.4 μ M for U0126 and 0.1 to 0.5 μ M for CI-1040 (Table 1). There was only the most marginal trend toward the MCF10A normal cell model being slightly less sensitive than the transformed cells to MEK inhibition in 2D culture. The results of MEK inhibition on growth in the 3D rBM overlay cultures were distinct, however (Fig. 3, B and D). Although U0126 still blocked the proliferation MCF10.H-Ras and N-Ras cells with comparable GI_{50} values to its action in 2D culture, the normal MCF10A model and the hyperplastic variants, MCF10.NeoT and MCF10.AT1, were not sensitive to this range of U0126 treatment (Table 1). The MCF10.DCIS dysplastic variant showed an intermediate response, with a partially resistant phenotype toward U0126. The results from treatment with CI-1040, which is a more potent inhibitor of ERK activation




Fig. 3. Dose-dependent analysis of growth inhibition of MCF10 variants by MEK inhibitors in 2D and 3D culture. A and C, cells were cultured in 96-well plates for 3 days with the indicated concentrations of U0126 or CI-1040 and subjected to MTT assay. B and D, cells were cultured for 9 days in 3D rBM overlay cultures with the indicated concentrations of U0126 or CI-1040 and the size of structures measured. The cell lines assayed were MCF10A, black open circles; MCF10.NeoT, magenta triangles; MCF10.AT1, orange triangles; MCF10.DCIS, red diamonds; MCF10.H-Ras, green circles; and MCF10.N-Ras, blue squares. Data shown are mean \pm S.E.M. ($n = 3$).

TABLE 1

Growth inhibition of breast cell lines by MEK inhibitors and doxorubicin in 2D and 3D rBM overlay cultures

Cell Line	GI ₅₀					
	U0126		CI-1040		Doxorubicin	
	2D	3D	2D	3D	2D	3D
			μM			
MCF10A	4.427	N.F.	0.482	N.F.	2.004	38.511
MCF10.NeoT	4.334	N.F.	0.178	0.587	0.575	13.518
MCF10.AT1	1.839	N.F.	0.304	0.838	1.167	22.926
MCF10.DCIS	4.324	N.F.	0.107	0.336	1.439	27.481
MCF10.H-Ras	3.328	2.100	0.151	0.003*	0.489	0.718
MCF10.N-Ras	2.794	3.740	0.134	0.002*	0.409	0.627
MDA-MB-231	96.879	6.325*	8.322	0.148*	16.083	26.140

N.F., the data did not fit to an inhibition curve that gave a GI₅₀ value within the range of concentrations tested.* $p < 0.05$ compared with corresponding value from 2D culture.

(Mattingly et al., 2006), showed even more difference in 3D rBM overlay culture from that seen in 2D culture (Fig. 3, C and D). The normal MCF10A model, the hyperplastic MCF10.NeoT and MCF10.AT1 cells, and the dysplastic MCF10.DCIS cells all showed an increase in GI₅₀ values for growth inhibition that indicated relative resistance to CI-1040 when cultured in 3D versus 2D. On the other hand, the transformed MCF10.H-Ras and N-Ras lines showed a dramatic and significant sensitization to CI-1040 inhibition, with GI₅₀ values reduced to the low nanomolar range (Table 1).

Because proliferation in 2D cultures had been assessed by MTT assay, whereas that in 3D cultures had been assayed by the size of structures that were formed, we further confirmed the effect of MEK inhibitors on the proliferation of the control MCF10A cells and the MCF10.H-Ras and N-Ras lines in 3D cultures by an adaptation of the MTT assay. The results (Supplemental Table 2) show very close alignment with those obtained by measurement of structure size (Table 1). In particular, the results confirm that MCF10.H-Ras and N-Ras cells show approximately 10-fold greater sensitivity to inhibition of proliferation by CI-1040 in 3D compared with 2D culture, when both assays are performed using the MTT protocol after 3 days of treatment.

The initial studies suggested that inhibition of the phosphatidylinositol 3'-kinase pathway, which is also downstream of activated Ras, may not be required for the proliferation of the MCF10 variants in 3D rBM overlay culture (Fig. 1). Because it is important to determine whether the sensitivity of the Ras-transformed cells in 3D culture represents a general response to inhibition of several pathways or a specific reliance on ERK pathway activation, we defined the action of wortmannin in more detail (Supplemental Fig. 1). Over the range of concentrations tested, we did not find any significant growth inhibition by wortmannin on the growth of any of the MCF10 variants in either 2D or 3D rBM overlay cultures (Supplemental Fig. 1, A and B). To confirm that this lack of effect was not caused by a failure to inhibit the activation of the phosphatidylinositol 3'-kinase/Akt pathway, we assayed the activation of that pathway in the cells and the effect of wortmannin (Supplemental Fig. 1C). In contrast to the data on ERK activation (Fig. 2), there is increased activation of Akt (as assayed by phosphorylation of Akt at Serine-473) only in the MCF10.DCIS cell line. The MCF10.H-Ras and N-Ras lines do not have increased Akt activation compared with that present in the normal MCF10A model or in the hyperplastic MCF10.NeoT or

MCF10.AT1 variants. This pattern of Akt activation is similar between the cells grown in 2D and 3D rBM overlay culture. In all the cell lines, wortmannin was able to effectively inhibit the activation of Akt, although it had no effect on cell proliferation (Supplemental Fig. 1).

Because cells derived from the breast and other tissues have typically been shown to have decreased sensitivity to growth inhibition in 3D culture conditions (Croix et al., 1996; Green et al., 1999; Desoize and Jardillier, 2000), we further tested whether the Ras-transformed MCF10 cells in rBM overlay culture had relative sensitivity or resistance to a cytotoxic treatment. Doxorubicin is one of the most widely used chemotherapeutic drugs and has an established role in treatment of basal-subtype and triple-negative breast cancer (Schneider et al., 2008). Therefore, we tested the growth inhibition induced by doxorubicin in 2D and 3D cultures of the MCF10 variants (Fig. 4). In 2D culture, all the MCF10 variants were similarly sensitive to inhibition of growth by doxorubicin, with GI₅₀ values between 0.4 and 2.0 μM . Once again, there was a marginal trend for the MCF10A normal model to be the least sensitive line tested. In 3D rBM overlay culture, the normal MCF10A cells (Fig. 1) and the less transformed hyperplastic and dysplastic models all exhibited significant resistance to doxorubicin (Fig. 4). GI₅₀ values increased to between 13.5 and 38.5 μM for inhibition of growth by doxorubicin in the MCF10A, NeoT, AT1, and DCIS cells. The MCF10.H-Ras and N-Ras cells, on the other hand, showed only a marginal resistance to doxorubicin when grown in 3D rBM overlay culture (Fig. 4). The GI₅₀ values slightly increased to 0.6 to 0.7 μM for inhibition of growth by doxorubicin in the MCF10.H-Ras and N-Ras cells (Table 1).

The results so far indicated that 3D rBM overlay culture revealed a relative and selective sensitization to MEK inhibition in Ras-driven MCF10 breast epithelial cells. To test whether this pattern of response was present in an independent model that includes endogenous Ras activation, we assayed the effects of MEK inhibitor and doxorubicin treatment on 2D and 3D rBM overlay cultures of MDA-MB-231 cells (Fig. 5). The results show that the MDA-MB-231 cells are relatively much more resistant to MEK inhibition in 2D culture than the MCF10 variants, with GI₅₀ values of 97 and 8.3 μM for U0126 and CI-1040, respectively (Table 1). These results are in close agreement with the recently published values of 60 and 33 μM (Mirzoeva et al., 2009). However, the change in sensitivity to MEK inhibition induced by 3D rBM overlay culture was even more striking than that seen for the




Fig. 4. Dose-dependent analysis of growth inhibition of MCF10 variants by doxorubicin in 2D and 3D culture. A, cells were cultured in 96-well plates for 3 days with the indicated concentrations of doxorubicin and subjected to MTT assay. B, cells were cultured for 9 days in 3D rBM overlay cultures with the indicated concentrations of doxorubicin and the size of structures measured. The cell lines assayed were MCF10A, black open circles; MCF10.NeoT, magenta triangles; MCF10.AT1, orange triangles; MCF10.DCIS, red diamonds; MCF10.H-Ras, green circles; and MCF10.N-Ras, blue squares. Data shown are mean \pm S.E.M. ($n = 3$).

Ras-driven MCF10 variants (Fig. 5B). The GI_{50} value for U0126 decreased to $6.3 \mu\text{M}$, whereas that for CI-1040 decreased to $0.15 \mu\text{M}$ (Table 1). In comparison, the response to doxorubicin showed a modest resistance when MDA-MB-231 cells were cultured in rBM overlay culture, with GI_{50} values of $16 \mu\text{M}$ in 2D and $26 \mu\text{M}$ in 3D (Table 1).

Discussion

The induction of relative resistance to growth inhibition by cytotoxic treatment when tumor cells are grown in 3D compared with 2D culture has been generally observed and proposed to be a better model of the response of tumors to therapy in vivo (Croix et al., 1996; Green et al., 1999; Desoize and Jardillier, 2000; Muir et al., 2006; Friedrich et al., 2007). Several mechanisms have been proposed to underlie this resistance, including decreased drug penetration and alterations in the signaling pathways in tumor cells that are able to form adhesion-dependent organization in 3D conditions (Green et al., 1999; Hurst et al., 2005). A classic study by Weaver et al. (2002) has previously investigated nonmalignant and tumorigenic variants of HMT-3522 human breast epithelial cells for their responsiveness to a variety of pro-

apoptotic treatments in 2D and 3D rBM overlay cultures. The results showed that although the nonmalignant and tumor cells were similarly sensitive in 2D culture, only the normal cells became resistant when they formed organized structures in the 3D system (Weaver et al., 2002). The results in the present study on the effects of doxorubicin in the MCF10 variants and in MDA-MB-231 cells in 2D versus 3D culture largely agree with these conclusions. There was a much larger increase in the GI_{50} value for doxorubicin treatment of the normal and hyperplastic variants of MCF10 cells than there was for the MCF10.H-Ras, N-Ras, or MDA-MB-231 cells when cultured in 3D rBM overlay culture. In this case, relative resistance to doxorubicin correlated with a reduced activation level of ERK in the 3D system of the normal and hyperplastic models. We have previously shown that acquired resistance to doxorubicin in neuroblastoma cells is associated with decreased ERK activation (Mattingly et al., 2001). Therefore, these results could suggest that combinations of kinase inhibitors that reduce ERK MAPK activation with doxorubicin chemotherapy may limit the efficacy of the cytotoxic component.

MEK inhibition in clinical trials has been generally well tolerated but marked by limited activity against malignancies that have included breast cancers (Rinehart et al., 2004;




Fig. 5. Dose-dependent analysis of growth inhibition of MDA-MB-231 cells in 2D and 3D culture. A, cells were cultured in 96-well plates for 3 days with the indicated concentrations of inhibitors and subjected to MTT assay. B, cells were cultured for 9 days in 3D rBM overlay cultures with the indicated concentrations of inhibitors and the size of structures measured. The inhibitors tested were U0126, filled circles; CI-1040, open circles; and doxorubicin, open triangles. Data shown are mean \pm S.E.M. ($n = 3$).

Adjei et al., 2008). The relative resistance of the normal MCF10A and hyperplastic models to growth inhibition by MEK inhibitors in 3D rBM overlay culture would be consistent with the lack of toxicity of this approach in vivo. More recently, Mirzoeva et al. (2009) have investigated MEK inhibition in a very large panel of breast cancer cell lines and concluded that a basal-like phenotype of breast cancer determines susceptibility to blockade of ERK activation. An implication of this result could be that a more focused clinical trial of MEK inhibitors in this particular subtype of breast cancer may be warranted. The basal subtype of breast cancer, which overlaps significantly with that defined to be "triple negative" by lack of expression of estrogen receptor, progesterone receptor, and HER2, is greatly in need of effective, targeted therapeutic approaches (Schneider et al., 2008). The MDA-MB-231 cell line, although phenotypically basal-subtype, was paradoxically the least sensitive of all the 46 cell lines previously profiled for response to MEK inhibition (Mirzoeva et al., 2009). The very high GI₅₀ values found for U0126 and CI-1040 in that study are similar to those determined in this study from the 2D cultures. The great increase in potency that we found for MEK inhibitors to block the proliferation of MDA-MB-231 cells that were grown in 3D rBM overlay culture (15-fold increase in sensitivity to U0126; 56-fold increase in sensitivity to CI-1040) provides a potential explanation for this discrepancy. For example, the potent ability of CI-1040 to block MDA-MB-231 proliferation in 3D with a GI₅₀ value of 0.15 μM would make that cell line more sensitive than any of the 46 lines tested for inhibition in 2D culture (Mirzoeva et al., 2009).

The most striking result from the current study is that rather than showing resistance to block of ERK activation in 3D culture, the MCF10.H-Ras, MCF10.N-Ras, and MDA-MB-231 cells all show a marked sensitization to growth inhibition after treatment with MEK inhibitors in rBM overlay culture. These results are consistent with previous data on the effects of an earlier generation and less potent MEK inhibitor, PD98059, on 3D rBM cultures of breast tumor cell lines (Wang et al., 1998, 2002). The sensitization that we have described to MEK inhibition was highly selective because 1) it did not occur in the MCF10A normal epithelial model or in the hyperplastic variants thereof; 2) there was no sensitivity to inhibition of the phosphatidylinositol 3'-kinase/Akt pathway that is also downstream of Ras activation; and 3) the increase in sensitivity to the targeted approach in the 3D rBM overlay cultures was accompanied by the expected relative resistance to cytotoxic treatment under the same conditions. More recently, a potentially similar result has also been published. Aggregates of HER2-positive breast and ovarian cancer cells growing in 3D are significantly more sensitive to growth inhibition by trastuzumab than the same cell lines growing in 2D (Pickl and Ries, 2009). Although we did not define a role for phosphatidylinositol 3'-kinase/Akt signaling, recent evidence suggests that combination blockade of both that pathway and MEK may be particularly effective in inhibition of basal-like breast cancers (Hoefflich et al., 2009).

In conclusion, the results of this study provide evidence that 3D overlay culture in rBM reveals a critical sensitivity to inhibition of ERK activation in two independent cell models of Ras-driven breast cancer that is not present in 2D cell culture. In contrast to the relative resistance to cytotoxic therapeutics that is observed in 3D culture, an increase in

potency of MEK inhibitors was described. The sensitivity to MEK inhibition was highly selective in that there was no sensitivity to the inhibition of the phosphatidylinositol 3'-kinase/Akt pathway that is also downstream of Ras activation, and that normal and hyperplastic models of breast epithelia showed relative resistance to MEK inhibition in 3D culture. Thus, it is reasonable to propose that 3D culture models may not only provide a better model for the relative resistance of tumor cells to cytotoxic therapy that is often found in vivo, but also that the 3D approach may also provide a superior method to identify the driving oncogenic pathways for tumor cells and critical inhibitors that may be effective for therapeutic trial.

Acknowledgments

We thank Pfizer, Inc. for the gift of CI-1040.

References

- Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, and Eckhardt SG (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. *J Clin Oncol* **26**:2139–2146.
- Allen LF, Sebolt-Leopold J, and Meyer MB (2003) CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). *Semin Oncol* **30**:105–116.
- Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, and Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. *Biochem J* **408**:297–315.
- Croix BS, Rak JW, Kapitan S, Sheehan C, Graham CH, and Kerbel RS (1996) Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. *J Natl Cancer Inst* **88**:1285–1296.
- Debnath J, Muthuswamy SK, and Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods* **30**:256–268.
- Desoize B and Jardillier J (2000) Multicellular resistance: a paradigm for clinical resistance? *Crit Rev Oncol Hematol* **36**:193–207.
- Eckert LB, Repasky GA, Ulku AS, McFall A, Zhou H, Sartor CI, and Der CJ (2004) Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. *Cancer Res* **64**:4585–4592.
- Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, and Trzaskos JM (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. *J Biol Chem* **273**:18623–18632.
- Friedrich J, Ebner R, and Kunz-Schughart LA (2007) Experimental anti-tumor therapy in 3-D: spheroids—old hat or new challenge? *Int J Radiat Biol* **83**:849–871.
- Green SK, Frankel A, and Kerbel RS (1999) Adhesion-dependent multicellular drug resistance. *Anticancer Drug Des* **14**:153–168.
- Hoefflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, and Lackner MR (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. *Clin Cancer Res* **15**:4649–4664.
- Hurst RE, Kamat CD, Kyker KD, Green DE, and Ihnat MA (2005) A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel. *Cancer Lett* **217**:171–180.
- Li Q and Mattingly RR (2008) Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. *Neoplasia* **10**:1444–1458.
- Li Q, Mullins SR, Sloane BF, and Mattingly RR (2008) p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. *Neoplasia* **10**:314–329.
- Mattingly RR, Kraniak JM, Dilworth JT, Mathieu P, Bealmeir B, Nowak JE, Benjamins JA, Tainsky MA, and Reiners JJ Jr (2006) The mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. *J Pharmacol Exp Ther* **316**:456–465.
- Mattingly RR, Milstein ML, and Mirkin BL (2001) Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells. *Cellular Signal* **13**:499–505.
- McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, and Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochim Biophys Acta* **1773**:1263–1284.
- McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, Bartlett JM, and Cooke TG (2009) Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. *Clin Cancer Res* **15**:1487–1495.
- Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B,

- Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, and Korn WM (2009) Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. *Cancer Res* **69**:565–572.
- Muir CP, Adams MA, and Graham CH (2006) Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. *Breast Cancer Res Treat* **96**:169–176.
- Pickl M and Ries CH (2009) Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. *Oncogene* **28**:461–468.
- Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, and Meyer MB (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. *J Clin Oncol* **22**:4456–4462.
- Roberts PJ and Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. *Oncogene* **26**:3291–3310.
- Schmeichel KL and Bissell MJ (2003) Modeling tissue-specific signaling and organ function in three dimensions. *J Cell Sci* **116**:2377–2388.
- Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, and Carey LA (2008) Triple-negative breast cancer: risk factors to potential targets. *Clin Cancer Res* **14**:8010–8018.
- Sharma SV and Settleman J (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. *Genes Dev* **21**:3214–3231.
- von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, and Boss GR (2000) Ras activation in human breast cancer. *Breast Cancer Res Treat* **62**:51–62.
- Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, and Bissell MJ (2002) Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. *J Natl Cancer Inst* **94**:1494–1503.
- Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, and Bissell MJ (1998) Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. *Proc Natl Acad Sci U S A* **95**:14821–14826.
- Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, and Bissell MJ (2002) beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. *Cancer Cell* **2**:205–216.

Address correspondence to: Raymond R. Mattingly, Wayne State University Department of Pharmacology, 540 East Canfield Avenue, Detroit, MI 48201. E-mail: r.mattingly@wayne.edu
